FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Anne-Marie O'Farrell

Research Profile

Chemicals & Drugs

Living Beings

Phenomena

Anatomy

Tumor Cells, Cultured

Disorders

Procedures

Administration, Oral

Physiology

Cell Divisions

Co-author Network

Publications

TOP 3
Anne-Marie O'Farrell; Andre van Vliet; Khalid Abou Farha; Julie M Cherrington; David A Campbell; Xinqiang Li; Denise Hanway; Jianke Li; Hans-Peter Guler
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
Marcus Schittenhelm; Kevin W H Yee; Jeffrey W Tyner; Laura McGreevey; Andrea Haley; Ajia Town; Diana J Griffith; Troy Bainbridge; Rita M Braziel; Anne-Marie O'Farrell; Julie M Cherrington; Michael C Heinrich
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Shem Patyna; A Douglas Laird; Dirk B Mendel; Anne-Marie O'Farrell; Chris Liang; Huiping Guan; Tomas Vojkovsky; Stefan Vasile; Xueyan Wang; Jeffrey Chen; Maren Grazzini; Cheng Y Yang; Joshua O Haznedar; Juthamas Sukbuntherng; Wei-Zhu Zhong; Julie M Cherrington; Dana Hu-Lowe
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Anne-Marie O'Farrell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Anne-Marie O'Farrell; Andre van Vliet; Khalid Abou Farha; Julie M Cherrington; David A Campbell; Xinqiang Li; Denise Hanway; Jianke Li; Hans-Peter Guler
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
Clinical therapeutics 2007;29(8):1692-705.
2006: Marcus Schittenhelm; Kevin W H Yee; Jeffrey W Tyner; Laura McGreevey; Andrea Haley; Ajia Town; Diana J Griffith; Troy Bainbridge; Rita M Braziel; Anne-Marie O'Farrell; Julie M Cherrington; Michael C Heinrich
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Leukemia 2006;20(11):2008-14.
2006: Shem Patyna; A Douglas Laird; Dirk B Mendel; Anne-Marie O'Farrell; Chris Liang; Huiping Guan; Tomas Vojkovsky; Stefan Vasile; Xueyan Wang; Jeffrey Chen; Maren Grazzini; Cheng Y Yang; Joshua O Haznedar; Juthamas Sukbuntherng; Wei-Zhu Zhong; Julie M Cherrington; Dana Hu-Lowe
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Molecular cancer therapeutics 2006;5(7):1774-82.
2005: Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood 2005;105(3):986-93.
2004: Kevin W H Yee; Marcus Schittenhelm; Anne-Marie O'Farrell; Ajia Town; Laura McGreevey; Troy Bainbridge; Julie M Cherrington; Michael C Heinrich
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Blood 2004;104(13):4202-9.
2004: Anne-Marie O'Farrell; Helene A Yuen; Beverly D Smolich; Alison L Hannah; Sharianne G Louie; Weiru Hong; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Judith E Karp; Maher Albitar; Julie M Cherrington; Francis Giles
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 2004;28(7):679-89.
2004: JC Young; S Wu; G Hansteen; C Du; Lidia C Sambucetti; Stacy W Remiszewski; Anne-Marie O'Farrell; B Hill; C Lavau; Lesley J Murray
Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal.
Cytotherapy 2004;6(4):328-36.
2003: Anne-Marie O'Farrell; James M Foran; Walter Fiedler; Hubert Serve; Ronald L Paquette; Maureen A Cooper; Helene A Yuen; Sharianne G Louie; Heidi Kim; Susan Nicholas; Michael C Heinrich; Wolfgang E Berdel; Carlo Bello; Mark Jacobs; Paul Scigalla; William C Manning; Stephen Kelsey; Julie M Cherrington
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5465-76.
2003: Walter Fiedler; Rolf M Mesters; Heike Tinnefeld; Sonja Loges; Peter Staib; Ulrich Duhrsen; Michael Flasshove; Oliver G Ottmann; Wolfram Jung; Franco Cavalli; Rolf Kuse; Joerg Thomalla; Hubert Serve; Anne-Marie O'Farrell; Mark Jacobs; Nicoletta M Brega; Paul Scigalla; Dieter K Hossfeld; Wolfgang E Berdel
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Blood 2003;102(8):2763-7.
2003: Francis Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Blood 2003;101(9):3597-605.
2003: Jastinder Sohal; Vernon T Phan; Philip V Chan; Elizabeth M Davis; Bhumi Patel; Louise M Kelly; Tinya J Abrams; Anne-Marie O'Farrell; D Gary Gilliland; Michelle M Le Beau; Scott C Kogan
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
Blood 2003;101(8):3188-97.
2003: Samuel E DePrimo; Lily M Wong; Deepak B Khatry; Susan L Nicholas; William C Manning; Beverly D Smolich; Anne-Marie O'Farrell; Julie M Cherrington
Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.
BMC cancer 2003;3():3.
2003: Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne-Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Clinical & experimental metastasis 2003;20(8):757-66.
2002: Kevin W H Yee; Anne-Marie O'Farrell; Beverly D Smolich; Julie M Cherrington; Gerald McMahon; Cecily L Wait; Laura McGreevey; Diana J Griffith; Michael C Heinrich
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Blood 2002;100(8):2941-9.